» Articles » PMID: 38927433

Optimizing Recombinant Cas9 Expression: Insights from BL21(DE3) Strains for Enhanced Protein Purification and Genome Editing

Overview
Journal Biomedicines
Date 2024 Jun 27
PMID 38927433
Authors
Affiliations
Soon will be listed here.
Abstract

The CRISPR-Cas9 system is a revolutionary tool in genetic engineering, offering unprecedented precision and efficiency in genome editing. Cas9, an enzyme derived from bacteria, is guided by RNA to edit DNA sequences within cells precisely. However, while CRISPR-Cas9 presents notable benefits and encouraging outcomes as a molecular tool and a potential therapeutic agent, the process of producing and purifying recombinant Cas9 protein remains a formidable hurdle. In this study, we systematically investigated the expression of recombinant SpCas9-His in four distinct () strains (Rosetta2, BL21(DE3), BL21(DE3)-pLysS, and BL21(DE3)-Star). Through optimization of culture conditions, including temperature and post-induction time, the BL21(DE3)-pLysS strain demonstrated efficient SpCas9 protein expression. This study also presents a detailed protocol for the purification of recombinant SpCas9, along with detailed troubleshooting tips. Results indicate successful SpCas9 protein expression using BL21(DE3)-pLysS at 0.5 mM IPTG concentration. Furthermore, the findings suggest potential avenues for further enhancements, paving the way for large-scale Cas9 production. This research contributes valuable insights into optimizing strains and culture conditions for enhanced Cas9 expression, offering a step forward in the development of efficient genome editing tools and therapeutic proteins.

Citing Articles

Advancements in Escherichia coli secretion systems for enhanced recombinant protein production.

Lokireddy S, Kunchala S, Vadde R World J Microbiol Biotechnol. 2025; 41(3):90.

PMID: 40025370 DOI: 10.1007/s11274-025-04302-0.

References
1.
Rajagopalan N, Kagale S, Bhowmik P, Song H . A Two-Step Method for Obtaining Highly Pure Cas9 Nuclease for Genome Editing, Biophysical, and Structural Studies. Methods Protoc. 2019; 1(2). PMC: 6526429. DOI: 10.3390/mps1020017. View

2.
Assenberg R, Wan P, Geisse S, Mayr L . Advances in recombinant protein expression for use in pharmaceutical research. Curr Opin Struct Biol. 2013; 23(3):393-402. DOI: 10.1016/j.sbi.2013.03.008. View

3.
Wang J, Doudna J . CRISPR technology: A decade of genome editing is only the beginning. Science. 2023; 379(6629):eadd8643. DOI: 10.1126/science.add8643. View

4.
Gheibi Hayat S, Farahani N, Golichenari B, Sahebkar A . Recombinant Protein Expression in Escherichia coli (E.coli): What We Need to Know. Curr Pharm Des. 2018; 24(6):718-725. DOI: 10.2174/1381612824666180131121940. View

5.
Raran-Kurussi S, Cherry S, Zhang D, Waugh D . Removal of Affinity Tags with TEV Protease. Methods Mol Biol. 2017; 1586:221-230. PMC: 7974378. DOI: 10.1007/978-1-4939-6887-9_14. View